Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
An article from
Dive Brief
Labcorp and Quest Diagnostics both plan to offer the test, which secured CE mark certification earlier this year.
Published Aug. 25, 2026
By
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
FDA Clears New Alzheimer’s Blood Test
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
FDA clears Roche and Eli Lilly Alzheimer's blood test
Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance | CNN
FDA Clears Blood Test to Detect Alzheimer's in Primary and Specialty Care
Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care
FDA Clears Novel Alzheimer's Blood Test
For the first time, new blood test can help detect Alzheimer’s from age 40
FDA clears PrecivityAD2, Alzheimer's disease blood test for as early as age 40 years
Labcorp to Offer First FDA-Cleared Blood Test to Detect Alzheimer's Disease Pathology in Both Primary and Specialty Care Settings
The new test promises to be “minimally invasive” and can help doctors identify symptoms of Alzheimer’s disease earlier.
The U.S. Food and Drug Administration has cleared another blood test that could help doctors identify whether memory problems are…
The U.S. Food and Drug Administration on Friday approved a new blood test for the early detection of Alzheimer's disease in…
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
The Elecsys pTau217 test can help doctors assess amyloid pathology in people 55 and older showing signs of cognitive decline
